v3.26.1
Stock-based Compensation - Narrative (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
May 31, 2023
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2025
USD ($)
shares
Dec. 31, 2025
USD ($)
Share-Based Payment Arrangement            
Stock-based compensation expense   $ 2,884 $ 78,747 $ (1,031) $ 106,389  
Accrued stock-based compensation   4,854   4,854   $ 8,256
Performance Shares            
Share-Based Payment Arrangement            
Stock-based compensation expense   2,100   (2,200) $ 106,400  
Accrued stock-based compensation   4,900   $ 4,900   $ 8,300
RSUs            
Share-Based Payment Arrangement            
Share-based award vesting period       1 year 7 months 6 days 1 year 8 months 12 days  
Unrecognized compensation cost   $ 5,200 $ 2,700 $ 5,200 $ 2,700  
Clinigence Holdings, Inc.            
Share-Based Payment Arrangement            
Conversion ratio   23.80952%        
Equity Incentive 2022 Plan            
Share-Based Payment Arrangement            
Share-based award vesting period       24 months    
Multiplying factor       10    
Equity Incentive 2022 Plan | Prior to the reverse stock split            
Share-Based Payment Arrangement            
Share price (in dollars per share) | $ / shares   $ 420.00   $ 420.00    
2023 Employee Stock Purchase Plan            
Share-Based Payment Arrangement            
Shares authorized (in shares) | shares 33,333          
Percentage of the market value at which employee stock purchase plan participants are entitled to purchase stock under the plan 85.00%          
Common stock issued for employee stock purchase plan (in shares) | shares   1,962 866 2,509 2,027